Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AGN-210961 Formulation 1 · 1 trial · 2 indications
IOP is a measurement of the fluid pressure inside the eye. Data are recorded at Hours 0, 2, 4, 6, 8, and 12. A negative number change from Baseline indicated a reduction in IOP (improvement). Data for bimatoprost-treated eyes are combined across groups.
IOP is a measurement of the fluid pressure inside the eye. Average IOP is the average of the 2 eyes for each patient at each time point. A negative number change from Baseline indicates a reduction in IOP (improvement). Data are recorded at Hours 0, 2, 4, 6, 8, and 12.
| Arm | Type | Description |
|---|---|---|
| Part 1, AGN-210961 Formulation 1 | EXPERIMENTAL | AGN-210961 Formulation 1 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days. |
| Part 1, AGN-210961 Formulation 2 | EXPERIMENTAL | AGN-210961 Formulation 2 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days. |
| Part 1, AGN-210961 Formulation 3 | EXPERIMENTAL | AGN-210961 Formulation 3 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days. |
| Part 1, AGN-210961 Formulation 4 | EXPERIMENTAL | AGN-210961 Formulation 4 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days. |
| Part 1, AGN-210961 Formulation 5 | EXPERIMENTAL | AGN-210961 Formulation 5 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days. |
| Part 1, AGN-210961 Formulation 6 | EXPERIMENTAL | AGN-210961 Formulation 6 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days. |
| Part 2, AGN-210961 Formulation 7 | EXPERIMENTAL | AGN-210961 Formulation 7 in both eyes once daily for 4 weeks. |
| Part 2, bimatoprost ophthalmic solution 0.03% | ACTIVE_COMPARATOR | bimatoprost ophthalmic solution 0.03% in both eyes once daily for 4 weeks. |
| Name | Type | Description |
|---|---|---|
| AGN-210961 Formulation 1 | DRUG | AGN-210961 Formulation 1 in one eye once daily for 7 days. |
| AGN-210961 Formulation 2 | DRUG | AGN-210961 Formulation 2 in one eye once daily for 7 days. |
| AGN-210961 Formulation 3 | DRUG | AGN-210961 Formulation 3 in one eye once daily for 7 days. |
| AGN-210961 Formulation 4 | DRUG | AGN-210961 Formulation 4 in one eye once daily for 7 days. |
| AGN-210961 Formulation 5 | DRUG | AGN-210961 Formulation 5 in one eye once daily for 7 days. |
| AGN-210961 Formulation 6 | DRUG | AGN-210961 Formulation 6 in one eye once daily for 7 days. |
| AGN-210961 Formulation 7 | DRUG | AGN-210961 Formulation 7 in both eyes once daily for 4 weeks. |
| bimatoprost ophthalmic solution 0.03% | DRUG | bimatoprost ophthalmic solution 0.03% (LUMIGAN®) in both eyes once daily for 4 weeks. |
Inclusion Criteria: \- Ocular hypertension or primary open-angle glaucoma in each eye Exclusion Criteria: * Any active ocular disease * Anticipated wearing of contact lenses during study * Anticipated use of artificial tears during study * Contraindication to pupil dilatation
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 2 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE1 | AGN-193408 |
| Glaukos Corp | GKOS | 1 | - | Travoprost |
AGN-210961 Formulation 1 is an investigational small molecule being developed by AbbVie Inc. for the treatment of ocular hypertension. It is formulated as an ophthalmic solution and has been studied in patients with ocular hypertension and primary open-angle glaucoma.
AGN-210961 Formulation 1 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The drug is an investigational small molecule in the ophthalmology therapeutic area.
AGN-210961 Formulation 1 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed, and no trials are currently active.
AGN-210961 Formulation 1 has been studied in one completed Phase 2 trial, NCT01110499. This randomized, double-blind, active-controlled study evaluated the safety and efficacy of AGN-210961 ophthalmic solution compared with bimatoprost ophthalmic solution in 163 patients with glaucoma or ocular hypertension in the United States.
No, AGN-210961 Formulation 1 is not the same as bimatoprost. In the completed Phase 2 trial NCT01110499, AGN-210961 ophthalmic solution was compared with bimatoprost ophthalmic solution, which served as the active control. They are distinct drug products.